Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019

Shingrix (Recombinant zoster vaccine, RZV) was approved in October 2017 in the United States (US) for the prevention of herpes zoster in adults aged 50 years and older. The vaccine is administered in two doses, with the second dose administration recommended between two and six months after the firs...

Descripción completa

Detalles Bibliográficos
Autores principales: Patterson, Brandon J., Chen, Chi-Chang, McGuiness, Catherine B., Glasser, Lisa I., Sun, Kainan, Buck, Philip O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475586/
https://www.ncbi.nlm.nih.gov/pubmed/33849373
http://dx.doi.org/10.1080/21645515.2021.1879579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8475586/
https://www.ncbi.nlm.nih.gov/pubmed/33849373
http://dx.doi.org/10.1080/21645515.2021.1879579

Ejemplares similares